The Journal of dermatology
Ritlecitinib in Alopecia Areata: A 24-Week Real-World Experience Contrasting JAK Inhibitor-Naïve and JAK Inhibitor-Experienced Patients.
Toshiki Okazaki, Takehiro Takahashi, Moyuka Wada-Irimada, Mana Sekine, Takuya Takahashi, Tomoko Chiba, Emi Yamazaki, Kosuke Shido, Toshiya Takahashi, Yoshihide Asano
Published: 202510.1111/1346-8138.70123
Abstract
Alopecia areata (AA) is a chronic autoimmune disorder characterized by refractory non-scarring hair loss. Although baricitinib revolutionized AA management, some severe cases remain refractory. Ritlecitinib, an oral selective dual JAK3 and tyrosine k…
Preview only. Read the full abstract at the source